vs
Side-by-side financial comparison of CG Oncology, Inc. (CGON) and NSTS Bancorp, Inc. (NSTS). Click either name above to swap in a different company.
NSTS Bancorp, Inc. is the larger business by last-quarter revenue ($2.5M vs $2.3M, roughly 1.1× CG Oncology, Inc.). NSTS Bancorp, Inc. runs the higher net margin — 214.3% vs -1779.0%, a 1993.3% gap on every dollar of revenue. On growth, CG Oncology, Inc. posted the faster year-over-year revenue change (409.2% vs 3.0%). NSTS Bancorp, Inc. produced more free cash flow last quarter ($3.9M vs $-36.2M).
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies for urological cancers including non-muscle invasive bladder cancer. It primarily operates in the U.S. market, advancing pipeline candidates to address unmet medical needs for patients with limited treatment options.
NSTS Bancorp, Inc. is a U.S.-based bank holding company. It offers a comprehensive suite of retail and commercial banking products and services, including deposit accounts, personal loans, commercial loans, and wealth management solutions, primarily serving individual consumers and small-to-medium enterprises in its regional operating areas.
CGON vs NSTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3M | $2.5M |
| Net Profit | $-41.3M | $135.0K |
| Gross Margin | — | — |
| Operating Margin | -2097.3% | — |
| Net Margin | -1779.0% | 214.3% |
| Revenue YoY | 409.2% | 3.0% |
| Net Profit YoY | -29.9% | 393.5% |
| EPS (diluted) | $-0.52 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3M | $2.5M | ||
| Q3 25 | $1.7M | $2.5M | ||
| Q2 25 | $0 | $2.5M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | $456.0K | $2.4M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $2.3M | ||
| Q1 24 | $529.0K | $2.0M |
| Q4 25 | $-41.3M | $135.0K | ||
| Q3 25 | $-43.8M | $65.0K | ||
| Q2 25 | $-41.4M | $-258.0K | ||
| Q1 25 | — | $-328.0K | ||
| Q4 24 | $-31.8M | $-46.0K | ||
| Q3 24 | — | $-171.0K | ||
| Q2 24 | — | $-326.0K | ||
| Q1 24 | $-16.9M | $-246.0K |
| Q4 25 | -2097.3% | — | ||
| Q3 25 | -3069.0% | 2.6% | ||
| Q2 25 | — | -10.1% | ||
| Q1 25 | — | -15.2% | ||
| Q4 24 | -8344.1% | -71.9% | ||
| Q3 24 | — | -7.6% | ||
| Q2 24 | — | -14.2% | ||
| Q1 24 | -4247.4% | -12.2% |
| Q4 25 | -1779.0% | 214.3% | ||
| Q3 25 | -2629.5% | 2.6% | ||
| Q2 25 | — | -10.1% | ||
| Q1 25 | — | -15.2% | ||
| Q4 24 | -6973.7% | -71.9% | ||
| Q3 24 | — | -7.6% | ||
| Q2 24 | — | -14.2% | ||
| Q1 24 | -3200.8% | -12.2% |
| Q4 25 | $-0.52 | — | ||
| Q3 25 | $-0.57 | $0.01 | ||
| Q2 25 | $-0.54 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-0.47 | — | ||
| Q3 24 | — | $-0.03 | ||
| Q2 24 | — | — | ||
| Q1 24 | $-0.36 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $742.2M | $34.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $752.6M | $80.0M |
| Total Assets | $791.6M | $266.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $742.2M | $34.0M | ||
| Q3 25 | $680.3M | $34.1M | ||
| Q2 25 | $661.1M | $47.5M | ||
| Q1 25 | — | $57.5M | ||
| Q4 24 | $742.0M | $53.5M | ||
| Q3 24 | — | $34.6M | ||
| Q2 24 | — | $32.4M | ||
| Q1 24 | $566.5M | $36.4M |
| Q4 25 | $752.6M | $80.0M | ||
| Q3 25 | $687.6M | $78.9M | ||
| Q2 25 | $670.4M | $77.8M | ||
| Q1 25 | — | $77.5M | ||
| Q4 24 | $733.4M | $76.5M | ||
| Q3 24 | — | $78.4M | ||
| Q2 24 | — | $76.5M | ||
| Q1 24 | $568.9M | $77.0M |
| Q4 25 | $791.6M | $266.6M | ||
| Q3 25 | $729.9M | $269.8M | ||
| Q2 25 | $701.4M | $276.0M | ||
| Q1 25 | — | $282.7M | ||
| Q4 24 | $754.8M | $278.7M | ||
| Q3 24 | — | $268.4M | ||
| Q2 24 | — | $265.9M | ||
| Q1 24 | $579.1M | $265.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-36.2M | $4.1M |
| Free Cash FlowOCF − Capex | $-36.2M | $3.9M |
| FCF MarginFCF / Revenue | -1560.0% | 156.9% |
| Capex IntensityCapex / Revenue | 0.3% | 4.1% |
| Cash ConversionOCF / Net Profit | — | 30.01× |
| TTM Free Cash FlowTrailing 4 quarters | $-124.1M | $4.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-36.2M | $4.1M | ||
| Q3 25 | $-38.9M | $2.9M | ||
| Q2 25 | $-28.0M | $655.0K | ||
| Q1 25 | — | $-2.7M | ||
| Q4 24 | $-20.7M | $9.4M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | $-26.0M | $92.0K |
| Q4 25 | $-36.2M | $3.9M | ||
| Q3 25 | $-39.0M | $2.9M | ||
| Q2 25 | $-28.0M | $616.0K | ||
| Q1 25 | — | $-2.7M | ||
| Q4 24 | $-20.9M | $9.1M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $-1.7M | ||
| Q1 24 | $-26.0M | $76.0K |
| Q4 25 | -1560.0% | 156.9% | ||
| Q3 25 | -2340.4% | 113.9% | ||
| Q2 25 | — | 24.2% | ||
| Q1 25 | — | -126.1% | ||
| Q4 24 | -4577.0% | 373.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | -76.4% | ||
| Q1 24 | -4919.5% | 3.8% |
| Q4 25 | 0.3% | 4.1% | ||
| Q3 25 | 5.8% | 0.1% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | 45.8% | 13.1% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | 2.3% | 0.8% |
| Q4 25 | — | 30.01× | ||
| Q3 25 | — | 44.03× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
